ASCO Update 2004: Focus on Prostate and Renal Cell Cancers Primo N. Lara, Jr., MD
description
Transcript of ASCO Update 2004: Focus on Prostate and Renal Cell Cancers Primo N. Lara, Jr., MD
ASCO Update 2004:ASCO Update 2004:Focus on Prostate and Focus on Prostate and
Renal Cell CancersRenal Cell CancersPrimo N. Lara, Jr., MDPrimo N. Lara, Jr., MD
Associate Professor Associate Professor
University of California University of California
Davis Cancer CenterDavis Cancer Center
Development of Hormonal EscapeDevelopment of Hormonal Escape
Prostate Cancer. London, England: Times Mirror International Publishers Ltd;1996:143.
Depriveandrogen
Cel
l num
bers
Time
Androgen-independentcells take over
Responsive
Dependent
Independent
Hormone Refractory Prostate CancerHormone Refractory Prostate Canceraka Androgen Independent Diseaseaka Androgen Independent Disease
Practical definition: consecutive series of increasing PSA levels after a nadir is reached with hormone therapy
Must have had a trial of anti-androgen withdrawal – 10-30% of patients will have a PSA response
Must have castrate levels of testosterone
Current Status 2004:Current Status 2004:Hormone Refractory Prostate CancerHormone Refractory Prostate Cancer
Benchmark median survival = 18 months Prognostic factors can predict response
and survival independent of therapy received
Survival and quality of life are most important outcome measures
Current Status 2004:Current Status 2004:Hormone Refractory Prostate CancerHormone Refractory Prostate Cancer
Chemotherapy results in prolongation of life, symptom control, and enhanced quality of life
Second-line hormonal therapies are generally ineffective
Novel molecular targeted therapies are now being integrated into treatment strategies
Treatment Goals in HRPCTreatment Goals in HRPC
Biochemical (PSA-only) diseaseBiochemical (PSA-only) disease
Metastatic disease: AsymptomaticMetastatic disease: Asymptomatic– Prolong life– Prevent morbidity: skeletal-related events, pain
Metastatic disease: SymptomaticMetastatic disease: Symptomatic– Palliate symptoms– Enhance quality of life– Prolong life
Prognostic factors in HRPCPrognostic factors in HRPC
PSA-related variables– Doubling time– Ratio of pre- and post-treatment slopes– PSA velocity
Prior prostatectomy Performance status Gleason score LDH Alkaline phosphatase Hemoglobin Presence of Visceral Disease
PSA-related variables as prognostic PSA-related variables as prognostic indicators in HRPCindicators in HRPC
Doubling time – PSADT < 4 months MST = 445 days– PSADT > 4 months MST = 746 days (p<0.001)
Pre-post treatment PSA ratios – Ratio –0.8 to –0.3 Hazard Ratio (survival) = 0.7 – Ratio > -0.3 Hazard Ratio = 1.0 (p=0.09)
PSA velocity – Measured within first 3 months of chemotherapy– Hazard ratio for death = 3.56 (p < 0.0001) for each unit
increase of PSA velocity
ASCO 2004: Nelson #4554, D’Amico #4506, Crawford #4505
Prognostic Variables for HRPC: Prognostic Variables for HRPC: CALGB DatabaseCALGB Database
Halabi, JCO 2003
Survival Distributions: Survival Distributions: CALGB Prognostic ModelCALGB Prognostic Model
Q1: 7.5 months Q2: 13.4 months Q3: 18.9 months
Q4: 27.2 months
Current Treatment Options: HRPCCurrent Treatment Options: HRPC
Supportive Care Radioisotopes and Palliative radiation Second line hormonal therapy Cytotoxic chemotherapy Investigational approaches
Cytotoxic Chemotherapy in HRPC: Cytotoxic Chemotherapy in HRPC: Active AgentsActive Agents
Cyclophosphamide Anthracyclines (e.g., mitoxantrone) Antimicrotubule agents
– Estramustine phosphate– Taxanes: docetaxel, paclitaxel– Vinca alkaloids: vinblastine
Randomized Trials of Mitoxantrone + Randomized Trials of Mitoxantrone + Steroid vs. Steroid Alone in HRPCSteroid vs. Steroid Alone in HRPC
Kantoff, et al Kantoff, et al
(JCO 1999) N=242(JCO 1999) N=242
Mitoxantrone + Dexamethasone
Dexa alone P-value
Median survival (months) 12.3 12.6 NS
Time to treatment failure or PD (months)
3.7 2.3 0.02
QOL/Pain control Better Worse N/A
Tannock, et al Tannock, et al
(JCO 1996) N=161(JCO 1996) N=161
Mitoxantrone + Prednisone
Prednisone alone
P-value
Median survival (months) 12 12 NS
Palliative response 29% 12% 0.01
Duration of palliation 43 weeks 18 weeks <0.0001
Docetaxel 70 mg/m2 Estramustine 280 po TID D1-5, 7-11 Q 21 d Prednisone 10 mg po QD HRPC PS 0-1 Docetaxel 35 mg/m2/wk x 3wks No prev Estramustine Q 28 d chemo N=120 Prednisone AAW Mitoxantrone 12 mg/m2 iv Prednisone
Q 21 d
RANDOMIZE
Oudard, pASCO 2003 #706
Randomized Phase II Trial of Randomized Phase II Trial of Docetaxel/Estramustine/Prednisone vs. Docetaxel/Estramustine/Prednisone vs. Mitoxantrone/PrednisoneMitoxantrone/Prednisone
N PSA50 RR
PSA NL
TTP (days)
CBR*
Bolus DEP 35 77% 20% 245 67%
Weekly DEP 33 65% 15% 188 58% MP 34 21% 3% 74 34%
* Clinical benefit response included pain control, analgesic use, pain index, PS
Oudard, pASCO 2003 #706
Randomized Phase II Trial of Randomized Phase II Trial of Docetaxel/Estramustine/Prednisone vs. Docetaxel/Estramustine/Prednisone vs. Mitoxantrone/PrednisoneMitoxantrone/Prednisone
A multicenter comparison of A multicenter comparison of docetaxel given weekly or every docetaxel given weekly or every three weeks + prednisone with three weeks + prednisone with mitoxantrone + prednisone in mitoxantrone + prednisone in
patients with hormone-refractory patients with hormone-refractory prostate cancer:prostate cancer:Study TAX-327Study TAX-327
Ronald De Wit M.D. PhDMario A.Eisenberger M.D.
Ian Tannock M.D. PhDand
TAX-327 investigators ASCO 2004 Abstract #4
TAX327Study Design
Stratification:
Pain levelPPI ≥ 2 or AS ≥ 10
vs.PPI < 2 or AS < 10
KPS≤70 vs. ≥ 80
Docetaxel 75 mg/m2 Q3 wks + Prednisone 5 mg bid
Mitoxantrone 12 mg/m2 Q3 wks +
Prednisone 5 mg bid
RANDOMIZE
Docetaxel 30 mg/m2 wkly 5 of 6 wks +
Prednisone 5 mg bid
Premedication: weekly docetaxel arm-dexamethasone 8 mg 1 hr prior to infusion; q3week docetaxel arm: dexamethasone 8 mg 12, 3, and 1 hour prior to infusion
Treatment duration in all 3 arms = 30 weeks
Grade 3-4Grade 3-4 Hematologic Toxicity (%) Hematologic Toxicity (%)
Docetaxel3 wkly
Docetaxelwkly
Mitoxantrone
Treated, n 332 330 335
Anemia 5 5 2
Neutropenia 32.0 1.5 22
Neutropenic infection
3.0 0.0 0.9
Febrile neutropenia 2.7 0.0 1.8
Septic death 0.0 0.3 0.3
Non-hematological ToxicityNon-hematological Toxicity(%)(%)
17 0.6 17 1.5 25 2.1Constipation
7 NA 37 NA30 NANail change
7 0.3 24 0.930 1.8Neuro-Sensory
10 1.2 34 4.832 2.1Diarrhea
36 1.5 36 2.441 2.7Nausea
35 5.1 49 5.553 4.5Fatigue
13 NA 50 NA65 NAAlopecia
All grades 3/4All grades 3/4All grades 3/4Toxicity
MitoxantroneDocetaxel wkly
Docetaxel 3 wkly
* NA = not applicable
Overall SurvivalOverall Survival
Mediansurvival Hazard
(mos) ratio P-value
Combined: 18.2 0.83 0.03D 3 wkly: 18.9 0.76 0.009D wkly: 17.3 0.91 0.3Mitoxantrone 16.4 – –
Months
Pro
bab
ilit
y o
f S
urv
ivin
g
0 6 12 18 24 30
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Docetaxel 3 wkly
Docetaxel wkly
Mitoxantrone
Overall SurvivalOverall Survival
Mediansurvival Hazard
(mos) ratio P-value
Combined: 18.2 0.83 0.03D 3wkly: 18.9 0.76 0.009D wkly: 17.3 0.91 0.3Mitoxantrone 16.4 – –
Months
Pro
bab
ilit
y o
f S
urv
ivin
g
0 6 12 18 24 30
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Docetaxel 3 wkly
Docetaxel wkly
Mitoxantrone
Quality of Life ResponseQuality of Life Response> 16 points FACT-P score > 16 points FACT-P score
compared to baselinecompared to baseline
Docetaxel
3-wkly
Docetaxel
wkly
Mitoxantrone
Evaluable, n 278 270 267
Response (%)
( 95% C.I )
22
(17-27)
23
(18-28)
13
(9-18)
P-value* 0.009 0.005
*Compared to mitoxantrone
Docetaxel and Estramustine versus Docetaxel and Estramustine versus Mitoxantrone and Prednisone in Men with Mitoxantrone and Prednisone in Men with Androgen Independent Prostate Cancer:Androgen Independent Prostate Cancer: Results of Southwest Oncology Group Results of Southwest Oncology Group
Intergroup Protocol 99-16Intergroup Protocol 99-16
Daniel P. Petrylak, M.D.1, Catherine M. Tangen, Dr.PH.2, Maha A. Hussain, M.D.3, Primo N. Lara Jr., M.D.4, Jeffrey A. Jones, M.D.5,
Mary Ellen Taplin, M.D.6, Patrick A. Burch, M.D.7, Graham F. Greene, M.D.8, Mitchell C. Benson, M.D.,1
Eric J. Small, M.D.9, Derek Raghavan, M.D., Ph.D,10 E. David Crawford, M.D.11
1Columbia University, New York, NY 2Southwest Oncology Group Statistical Center, Seattle, WA 3University of Michigan Comprehensive Cancer Center, Ann
Arbor, MI 4University of California, Davis, Sacramento, CA 5Baylor College of Medicine, Houston, TX 6University of Massachusetts Medical Center, Worcester, MA 7Mayo Clinic, Rochester, MN 8University of Arkansas for Medical Science,
Little Rock, AR 9University of California San Francisco Cancer Center, San Francisco, CA 10Cleveland Clinic Foundation, Cleveland, OH 11University of
Colorado Health Science Center, Denver, CO
ASCO 2004 Abstract #3
Schema: S9916Schema: S9916
D/E*Docetaxel 60 mg/m2 IV D2 every 21 days
Estramustine 280 mg po TID, D1-5Premedication: Dexamethasone 20 mg PO TID starting evening of D1
M/PMitoxantrone 12 mg/m2 IV every 21 daysPrednisone 5 mg po BID continuously
*Per protocol amendment January 15, 2001: Coumadin 2 mg PO daily + ASA 325 mg PO daily was added
Docetaxel and mitoxantrone doses could be increased to 70 mg/m2 and 14 mg/m2, respectively, if no grade 3 or 4 toxicities were seen in cycle 1
R Patient Stratification: Type of progression (progression of measurable or evaluable disease vs. increasing
PSA only; NCI CTC pain scale grade < 2 vs > 2; SWOG PS status 0-1 vs 2-3
Grade Grade >> 3 toxicity 3 toxicity
10
12
14
16
18
20
0
2
4
6
8
Pain Neurologic Metabolic Infection Hematologic GI Flu-like symptoms
Cardiovascular
D/E M/P
% o
f p
atie
nts
- there was no difference in toxic deaths between treatment arms
PSA Response RatePSA Response Rate
50%
27%
0%
10%
20%
30%
40%
50%
Docetaxel/estramustinen = 303
Mitoxantrone/prednisonen = 303
% o
f p
ati
en
ts w
ith
a >
50
% d
ec
rea
se
in
PS
A
p < 0.0001
Stratified by Treatment Arm
0%
20%
40%
60%
80%
100%
0 12 24 36 48Months
D+E
M+P
# at Risk324
324
# of Events
297
300
Medianin Months
6
3
HR: 0.73 (95% CI 0.63, 0.86), p < 0.0001
Progression Free Survival
0%
20%
40%
60%
80%
100%
0 12 24 36 48Months
D+EM+P
# at Risk
338 336
# of Deaths
217235
Medianin Months
1816
HR: 0.80 (95% CI 0.67, 0.97), p = 0.01
Overall Survival
Conclusions: Conclusions: TAX 327 & SWOG 9916TAX 327 & SWOG 9916
Docetaxel-based chemotherapy improves– Overall survival– Progression-free survival– Quality of life (Tax 327)
Contribution of estramustine is questionable
Reference standard for future studies in metastatic HRPC should be docetaxel
Bortezomib and Proteasome Bortezomib and Proteasome InhibitionInhibition
19SCap
20SSubunit
Chymo-tryptic
Site
Post-Glutamyl
Site
TrypticSite
1 2
3
4
5
6
7
26S Proteasome
Degrades ubiquitinated proteins Proteolysis is ATP-dependent
Bortezomib
19SCap
Chymotryptic site is rate-limiting in protein degradation
J Bio Chem. 1999; 274(32): 22123-22126; Science. 1995; 268(5210) 579-582; Bioorg Med Chem Lett. 1998; 8(4): 333-338.
Bortezomib in Combination with Bortezomib in Combination with DocetaxelDocetaxel
In vitro– Showed additive growth inhibition and apoptosis in
LNCaP and PC-3 prostate cancer cells
In vivo– In pancreatic xenograft models, bortezomib + docetaxel
demonstrated enhanced:• Reduction of tumor mass• p21 accumulation• Inhibition of tumor cell proliferation• Increased apoptosis• Reduced tumor microvessel density
Phase I/II Trial of Bortezomib Plus Phase I/II Trial of Bortezomib Plus Docetaxel in Patients With Advanced Docetaxel in Patients With Advanced Androgen-Independent Prostate CancerAndrogen-Independent Prostate Cancer
R. Dreicer,R. Dreicer,11 B. Roth, B. Roth,22 D. Petrylak, D. Petrylak,33 D. Agus, D. Agus,44 M. Meyers, M. Meyers,55 D. Esseltine,D. Esseltine,66 D. Rodriguez, D. Rodriguez,66 P. Oppedisano, P. Oppedisano,66 K. Wang, K. Wang,66 A. BoralA. Boral66
11Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; 22Vanderbilt-Ingram Cancer Center, Vanderbilt-Ingram Cancer Center, Nashville, TN; Nashville, TN; 33Columbia University, New York, NY; Columbia University, New York, NY; 44Cedars-Sinai Prostate Cancer Cedars-Sinai Prostate Cancer Center, Los Angeles, CA; Center, Los Angeles, CA; 55Aventis Oncology, Bridgewater, NJ; Aventis Oncology, Bridgewater, NJ; 66Millennium Millennium Pharmaceuticals, Cambridge, MAPharmaceuticals, Cambridge, MA
ASCO 2004, Abstract #4654
Treatment ScheduleTreatment Schedule
Docetaxel 1x/wk (days 1 and 8), bortezomib 1x/wk (days 2 and 9) every 21 days
24 hours between docetaxel and bortezomib Dexamethasone 8 mg night before, morning of,
and evening after each docetaxel infusion
1 Cycle
Day 1 982
D D B B
D = docetaxelB = bortezomib
Rest
21
Dreicer et al, ASCO 2004 Abstract 4654
Results From Phase I: Results From Phase I: Dose-Escalation SummaryDose-Escalation Summary
No DLTs have been reported
MTD not reached
Cohort 4 (40 mg/m2 docetaxel + 1.3 mg/m2 bortezomib) expanded to further assess safety, tolerability, and efficacy
Data on phase II assessment of cohort 4 to be presented (N = 32)
Dreicer et al, ASCO 2004 Abstract 4654
Conclusions: Bortezomib + Conclusions: Bortezomib + DocetaxelDocetaxel
Combination bortezomib and docetaxel at doses below MTD demonstrated promising activity
PR rate 23%
PSA decrease by ≥ 50% confirmed in 24% of patients
All measurable tumor responses and the majority of PSA responses were observed in patients who received prior chemotherapy
Measurable tumor response was observed in 1 patient who had received prior taxane therapy
Combination of docetaxel and bortezomib was well tolerated at doses assessed; adverse events were primarily low grade and manageable
Dreicer et al, ASCO 2004 Abstract 4654
A Phase II Trial of Epothilone-B Analogue BMS-247550 (NSC #710428) Administered Every 21
Days in Patients with Hormone Refractory Prostate Cancer: Southwest Oncology Group
Study S0111
M. Hussain, J. Faulkner, U. Vaishampayan, P. Lara, D. Petrylak, D. Colevas, W. Sakr, E.D.
Crawford
ASCO 2004 Abstract # 5410
SWOG- 0111SWOG- 0111 RationaleRationale
Epothilone-B Analogue BMS-247550:– New class of non-taxane tubulin polymerizing agents
resulting in mitotic arrest at G2/M transition.– High level of anti-tumor activity against in-vitro and
in-vivo tumor models that are naturally resistant or acquired resistance to paclitaxel.
– More potent than paclitaxel in tumor models.
Taxanes have demonstrated activity in patients with hormone refractory prostate cancer.
SWOG- 0111SWOG- 0111Treatment PlanTreatment Plan
Premedication: 1hr prior to BMS-247550:
Diphenhydramine 50 mg PORanitidine 150 mg PO
BMS-247550: 40 mg/m2 IV over 3hrsQ 21 days.
Registration
• PSA was monitored prior to each course.
• Objective response was assessed after every 2 courses
SWOG- 0111SWOG- 0111 PSA ResponsePSA Response
Confirmed Response 14 34%
Unconfirmed Response
2 5%
No Response 20 49%
Not Determinable 5 12%
Total 41 100%
Confirmed PSA response = 34% (95% CI: 20% to 51%)
SWOG- 0111SWOG- 0111 ConclusionsConclusions
In a cooperative group setting single agent Epothilone-B In a cooperative group setting single agent Epothilone-B analogue (BMS-247550) is active in patients with metastatic analogue (BMS-247550) is active in patients with metastatic hormone refractory prostate cancer.hormone refractory prostate cancer.
The most frequent high grade toxicities were hematologic The most frequent high grade toxicities were hematologic and neurotoxicities.and neurotoxicities.– There were no G5 toxicitiesThere were no G5 toxicities– 31% of patient were removed from study due to toxicity.31% of patient were removed from study due to toxicity.– Measures to counteract the neuropathy effects are Measures to counteract the neuropathy effects are
needed.needed.
Further studies are warranted to define this agent’s activity:Further studies are warranted to define this agent’s activity:– in first line treatment relative to standard therapy. in first line treatment relative to standard therapy. – in the second line setting. in the second line setting.
SUMMARY: HRPCSUMMARY: HRPC HRPC is a virulent, incurable disease Aggressive palliative care must be
pursued in the absence of cure Although docetaxel-based
chemotherapy can now be considered standard treatment for metastatic HRPC, the results remain suboptimal
Whenever possible, the “standard of care” for HRPC should still be clinical trial participation
Renal Cell Carcinoma 2004Renal Cell Carcinoma 2004
~32,000 new cases; ~12,000 deaths~32,000 new cases; ~12,000 deaths Five year survival rate for Five year survival rate for
metastatic disease is 0-10%metastatic disease is 0-10% Immunotherapy with interleukin-2 Immunotherapy with interleukin-2
or interferon-alfa has generally yielded or interferon-alfa has generally yielded modest clinical benefitsmodest clinical benefits
New agents with unique mechanisms New agents with unique mechanisms of action are neededof action are needed
Image from urotext.com
ECOG 3898: Low Dose Interferon +/- ECOG 3898: Low Dose Interferon +/- Thalidomide in Advanced RCCThalidomide in Advanced RCCGordon, et al. ASCO 2004, Abstract 4516Gordon, et al. ASCO 2004, Abstract 4516
RANDOMIZE
Interferon alfa 2B 1M units SQ BID
N=353
Metastatic or locally advanced RCC
PS 0-2
(84% power to detect a 50% increase in MST from 12 to 18 months)
Interferon alfa 2B 1M units SQ BID
Thalidomide 200 mg q HS (escalated to max of 1 g)
From: Kaelin, ASCO 2004
From: Kaelin, ASCO 2004
#4502
Bevacizumab + Erlotinib in RCC
Hainsworth, et al ASCO 2004
SU11248 in Renal Cell Carcinoma: Survival Curves
Preliminary Antitumor Activity ofPreliminary Antitumor Activity ofBAY 43-9006 in Metastatic Renal Cell BAY 43-9006 in Metastatic Renal Cell
Carcinoma and Other Advanced Refractory Carcinoma and Other Advanced Refractory Solid Tumors in a Phase II Randomized Solid Tumors in a Phase II Randomized
Discontinuation Trial (RDT)Discontinuation Trial (RDT)
Mark J. Ratain MD, KT Flaherty, WM Stadler, P O'Dwyer, S Kaye,H Xiong, A Patnaik, M Gore, RJ Lee, T Eisen
ASCO 40th Annual MeetingJune 5, 2004
New Orleans, Louisiana
#4501#4501
– Designed as a CRAF-targeted agent Also inhibits wild-type and mutant BRAF
– Recently demonstrated to inhibit other targets VEGFR-2, PDGFR-b, FLT-3 and c-KIT
N
CF3
Cl
NH
NH
OO
NH
O
CH3
BAY 43-9006 (sorafenib)BAY 43-9006 (sorafenib)A Novel RAF Kinase and VEGFR InhibitorA Novel RAF Kinase and VEGFR Inhibitor
BAY 43-9006 (sorafenib) Study 100391 BAY 43-9006 (sorafenib) Study 100391 Trial SchemaTrial Schema
* May cross over to BAY 43-9006
12 Week Induction
> 25% Shrinkage Continue BAY 43-9006
Open Label
> 25% GrowthOff study
BAY 43-9006
Placebo*
Tumor Assessment
Baseline 12 weeks 24 weeks
>-25% to <25%Randomized
BAY 43-9006 (sorafenib) Study 100391 BAY 43-9006 (sorafenib) Study 100391 Enrollment by Tumor TypeEnrollment by Tumor Type
ColorectalMelanoma
Sarcoma
Pancreas
Ovarian
Thyroid
Renal Cell
Other
Total number of patients: 484
28%
42%
8%5%
BAY 43-9006 (sorafenib) Study 100391 BAY 43-9006 (sorafenib) Study 100391 RCC Bidimensional Tumor Measurements* at Week RCC Bidimensional Tumor Measurements* at Week 12:12:Change from Baseline in Target Lesions (n=89)Change from Baseline in Target Lesions (n=89)
-100
-80
-60
-40
-20
0
20
40
60
80
100
120
% C
ha
ng
e i
n T
um
or
Me
as
ure
me
nt
Number of Patients
> 25% Growth
< 25% to >-25% Change
>-25% to -49% Shrinkage
> -50% Shrinkage
7 7
45** 24 1345** 24 13
* Investigator assessed
* * 7 of 45 patients not randomized
BAY 43-9006 (sorafenib) Study 100391 BAY 43-9006 (sorafenib) Study 100391 Progression-Free Survival in RCC Patients Progression-Free Survival in RCC Patients Continuing Beyond Initial 12 WeeksContinuing Beyond Initial 12 Weeks
* Responders at 12 week assessment with >25% tumor shrinkage
12 Weeks 24 Weeks
Open Label BAY (n=37)Median = 48 weeks(88% progression free at 24 weeks)
Randomized (n=38) Median = 23 weeks(41% progression free at 24 weeks)
Epothilone B Analog (BMS 247550) in Epothilone B Analog (BMS 247550) in Metastatic RCCMetastatic RCC
Zhuang, et al. ASCO 2004, Abstract #4550Zhuang, et al. ASCO 2004, Abstract #4550
N = 54 BMS 247550 6 mg/m2/day x 5 days q 3 wks PR in 8 patients (15%) Seven additional patients had minor
responses Overall “response” rate (PR + MR) = 28% No grade 4 neuropathy observed
Epothilone B Analog (BMS 247550) in Epothilone B Analog (BMS 247550) in Metastatic RCCMetastatic RCC
Zhuang, et al. ASCO 2004, Abstract #4550Zhuang, et al. ASCO 2004, Abstract #4550
INFLIXIMAB: INFLIXIMAB: A Phase II Trial of the A Phase II Trial of the Tumour Necrosis Factor (TNFTumour Necrosis Factor (TNF) )
Monoclonal Antibody in Patients with Monoclonal Antibody in Patients with Advanced Renal Cell CancerAdvanced Renal Cell Cancer
N. R. Maisey, K. Hall, C. Lee, E. Timotheadou, R. Ahern, T. Eisen, M. Gore
Royal Marsden HospitalInstitute of Cancer Research
London, UK
#4514#4514
TNFRCC
RENAL CELL CANCER RENAL CELL CANCER TNFTNF
DNA damage / inhibition of repair
Neo-angiogenesis
Induction of MMP
Inflammatory mediators
motility and invasion
Chemoresistance
Cachexia
INFLIXIMAB INFLIXIMAB TNF TNF neutralization neutralization
Target cell
TNF receptor
Target cell
TNF
Infliximab
Baseline 84 days
RENAL CELL CANCER Infliximab, responder 2
12 weeks 21 weeks
6 weeksBaseline
RENAL CELL CANCER Infliximab, late responder
INFLIXIMAB IS ACTIVE
PR = 16% (+ ‘late responder’,
21%)
PR + SD med duration = 340 days (124-361)
All pts 1 year OS = 55%
NON-TOXIC (1 pt with allergic reaction)
CONVENIENT
RENAL CELL CANCER RENAL CELL CANCER Infliximab, conclusionsInfliximab, conclusions
TNFTNF - a new target - a new target
Summary: Renal Cell Cancer Summary: Renal Cell Cancer ASCO 2004 a “watershed year” for RCC Clinical activity in seen with:
– Angiogenesis inhibitors• SU11248• Bevacizumab + OSI-774• BAY 43-9006
– Antimicrotubule• Epothilone B analog (BMS 247550)
– Anti-TNF• Iinfliximab
Randomized trials with these new compounds are essential (and ongoing)
(And BTW, thalidomide was a bust)